BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35280813)

  • 1. Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions.
    Jin P; Yang L; Qiao X; Hu C; Hu C; Wang X; Bao J
    Front Oncol; 2022; 12():840786. PubMed ID: 35280813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL.
    Lu Y; Li B; Huang H; Leng Q; Wang Q; Zhong R; Huang Y; Li C; Yuan R; Zhang Y
    Front Oncol; 2022; 12():1020317. PubMed ID: 36582803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
    Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
    J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone.
    Zhao YY; Xiong ML; Liu YF; Duan LJ; Chen JL; Xing Z; Lin YS; Chen TH
    Front Oncol; 2023; 13():1247682. PubMed ID: 38074651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
    Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
    Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
    Front Oncol; 2021; 11():825429. PubMed ID: 35155214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer.
    Li L; Shiradkar R; Tirumani SH; Bittencourt LK; Fu P; Mahran A; Buzzy C; Stricker PD; Rastinehad AR; Magi-Galluzzi C; Ponsky L; Klein E; Purysko AS; Madabhushi A
    Eur J Radiol Open; 2023; 10():100496. PubMed ID: 37396490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-Based Surrogate Imaging Markers of Aggressiveness in Prostate Cancer: Development of a Machine Learning Model Based on Radiomic Features.
    Dominguez I; Rios-Ibacache O; Caprile P; Gonzalez J; San Francisco IF; Besa C
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.
    Brancato V; Aiello M; Basso L; Monti S; Palumbo L; Di Costanzo G; Salvatore M; Ragozzino A; Cavaliere C
    Sci Rep; 2021 Jan; 11(1):643. PubMed ID: 33436929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer.
    Zhang Y; Chen W; Yue X; Shen J; Gao C; Pang P; Cui F; Xu M
    Front Oncol; 2020; 10():888. PubMed ID: 32695660
    [No Abstract]   [Full Text] [Related]  

  • 14. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions.
    Hou Y; Bao ML; Wu CJ; Zhang J; Zhang YD; Shi HB
    Abdom Radiol (NY); 2020 Dec; 45(12):4223-4234. PubMed ID: 32740863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.
    Chen T; Zhang Z; Tan S; Zhang Y; Wei C; Wang S; Zhao W; Qian X; Zhou Z; Shen J; Dai Y; Hu J
    Front Oncol; 2021; 11():792456. PubMed ID: 35127499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters.
    Woźnicki P; Westhoff N; Huber T; Riffel P; Froelich MF; Gresser E; von Hardenberg J; Mühlberg A; Michel MS; Schoenberg SO; Nörenberg D
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
    Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
    Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.